{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:38:20Z","timestamp":1793039900588,"version":"4.5.0"},"reference-count":224,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007188","name":"Uniformed Services University of the Health Sciences","doi-asserted-by":"publisher","award":["Dean\u2019s Research and Education Endowment Fund"],"award-info":[{"award-number":["Dean\u2019s Research and Education Endowment Fund"]}],"id":[{"id":"10.13039\/100007188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Intramural Research Program"],"award-info":[{"award-number":["Intramural Research Program"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Epstein-Barr virus (EBV) is the first human tumor virus discovered and is strongly implicated in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated cancers account for over 200,000 new cases of cancer and cause 150,000 deaths world-wide. EBV is also the primary cause of infectious mononucleosis, and up to 70% of adolescents and young adults in developed countries suffer from infectious mononucleosis. In addition, EBV has been shown to play a critical role in the pathogenesis of multiple sclerosis. An EBV prophylactic vaccine that induces neutralizing antibodies holds great promise for prevention of EBV associated diseases. EBV envelope proteins including gH\/gL, gB and gp350 play key roles in EBV entry and infection of target cells, and neutralizing antibodies elicited by each of these proteins have shown to prevent EBV infection of target cells and markedly decrease EBV titers in the peripheral blood of humanized mice challenged with lethal dose EBV. Recent studies demonstrated that immunization with the combination of gH\/gL, gB and\/or gp350 induced markedly increased synergistic EBV neutralizing activity compared to immunization with individual proteins. As previous clinical trials focused on gp350 alone were partially successful, the inclusion of gH\/gL and gB in a vaccine formulation with gp350 represents a promising approach of EBV prophylactic vaccine development. Therapeutic EBV vaccines have also been tested clinically with encouraging results. Immunization with various vaccine platforms expressing the EBV latent proteins EBNA1, LMP1, and\/or LMP2 promoted specific CD4+ and CD8+ cytotoxic responses with anti-tumor activity. The addition of EBV envelope proteins gH\/gL, gB and gp350 has the potential to increase the efficacy of a therapeutic EBV vaccine. The immune system plays a critical role in the control of tumors, and immune cell therapy has emerged as a promising treatment of cancers. Adoptive T-cell therapy has been successfully used in the prevention and treatment of post-transplant lymphoproliferative disorder. Chimeric antigen receptor T cell therapy and T cell receptor engineered T cell therapy targeting EBV latent proteins LMP1, LMP2 and\/or EBNA1 have been in development, with the goal to increase the specificity and efficacy of treatment of EBV associated cancers.<\/jats:p>","DOI":"10.3389\/fimmu.2021.734471","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T16:03:13Z","timestamp":1633881793000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":173,"title":["Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases"],"prefix":"10.3389","volume":"12","author":[{"given":"Xinle","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford M.","family":"Snapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"107fs7","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention","volume":"3","author":"Cohen","year":"2011","journal-title":"Sci Transl Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399404008440","article-title":"Infectious Mononucleosis and Epstein-Barr Virus","volume":"6","author":"Vetsika","year":"2004","journal-title":"Expert Rev Mol Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.09.041","article-title":"The Need and Challenges for Development of an Epstein-Barr Virus Vaccine","author":"Cohen","year":"2013","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMcp1001116","article-title":"Infectious Mononucleosis","volume":"362","author":"Luzuriaga","year":"2010","journal-title":"N Engl J Med"},{"key":"B5","article-title":"Infectious Mononucleosis at the United States Military Academy. A Prospective Study of a Single Class Over Four Years","volume":"47","author":"Hallee","year":"1974","journal-title":"Yale J Biol Med"},{"key":"B6","article-title":"Prospective Study of the Natural History of Infectious Mononucleosis Caused by Epstein-Barr Virus","volume":"14","author":"Rea","year":"2001","journal-title":"J Am Board Fam Pract"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-7230-7_22","article-title":"Vaccine Development for Epstein-Barr Virus","volume":"1045","author":"Cohen","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"B8","article-title":"Malignancies Associated With Epstein-Barr Virus: Pathobiology, Clinical Features, and Evolving Treatments","volume":"12","author":"Neparidze","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2010.02533.x","article-title":"Epstein-Barr Virus and Gastric Carcinoma","volume":"60","author":"Fukayama","year":"2010","journal-title":"Pathol Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21731","article-title":"The Global Health Burden of Infection-Associated Cancers in the Year 2002","volume":"118","author":"Parkin","year":"2006","journal-title":"Int J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.18.1522","article-title":"Risk of Hodgkin\u2019s Disease and Other Cancers After Infectious Mononucleosis","volume":"92","author":"Hjalgrim","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14603","article-title":"Comprehensive Review of Post-Organ Transplant Hematologic Cancers","volume":"18","author":"Dharnidharka","year":"2018","journal-title":"Am J Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14020","article-title":"The Role of Antiviral Prophylaxis for the Prevention of Epstein-Barr Virus-Associated Posttransplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review","volume":"17","author":"AlDabbagh","year":"2017","journal-title":"Am J Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-381921","article-title":"EBV-Associated T\/NK-Cell Lymphoproliferative Diseases in Nonimmunocompromised Hosts: Prospective Analysis of 108 Cases","volume":"119","author":"Kimura","year":"2012","journal-title":"Blood"},{"key":"B16","article-title":"Aggressive Natural Killer Cell Leukemia: Clinical Features and Treatment Outcome","volume":"87","author":"Song","year":"2002","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/103.3.308","article-title":"The Role of Epstein-Barr Virus in Lymphoepithelioma-Like Carcinomas","volume":"103","author":"Iezzoni","year":"1995","journal-title":"Am J Clin Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2174\/138955710792007150","article-title":"New Strategies and Patent Therapeutics in EBV-Associated Diseases","volume":"10","author":"Villegas","year":"2010","journal-title":"Mini Rev Med Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12212","article-title":"Does EBV Alter the Pathogenesis of Malaria","volume":"37","author":"Matar","year":"2015","journal-title":"Parasite Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"154945","DOI":"10.1016\/j.cyto.2019.154945","article-title":"Determination of the Cytokine Levels in Fetal Pleural Effusion and Their Association With Fetal\/Neonatal Findings","volume":"127","author":"Imai","year":"2020","journal-title":"Cytokine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1605906","article-title":"Prophylactic and Therapeutic Strategies for Epstein-Barr Virus-Associated Diseases: Emerging Strategies for Clinical Development","volume":"18","author":"Dasari","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"B22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein-Barr Virus and Cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1968.03140030037009","article-title":"Infectious Mononucleosis. Clinical Manifestations in Relation to EB Virus Antibodies","volume":"203","author":"Niederman","year":"1968","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2548","article-title":"Fusing Structure and Function: A Structural View of the Herpesvirus Entry Machinery","volume":"9","author":"Connolly","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00445-07","article-title":"Epstein-Barr Virus Entry","volume":"81","author":"Hutt-Fletcher","year":"2007","journal-title":"J Virol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coviro.2013.12.001","article-title":"Epstein Barr Virus Entry; Kissing and Conjugation","volume":"4","author":"Shannon-Lowe","year":"2014","journal-title":"Curr Opin Virol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.232381299","article-title":"Glycoprotein Gp110 of Epstein-Barr Virus Determines Viral Tropism and Efficiency of Infection","volume":"99","author":"Neuhierl","year":"2002","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-008-7570-z","article-title":"Entry of Herpesviruses Into Mammalian Cells","volume":"65","author":"Heldwein","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.2008.00681.x","article-title":"Laser-Capture Microdissection of Oropharyngeal Epithelium Indicates Restriction of Epstein-Barr Virus Receptor\/CD21 mRNA to Tonsil Epithelial Cells","volume":"37","author":"Jiang","year":"2008","journal-title":"J Oral Pathol Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.5.1405","article-title":"Characterization of an Epstein-Barr Virus Receptor on Human Epithelial Cells","volume":"176","author":"Birkenbach","year":"1992","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-82-10-2373","article-title":"Roles of Epstein-Barr Virus Glycoproteins Gp350 and Gp25 in the Infection of Human Epithelial Cells","volume":"82","author":"Maruo","year":"2001","journal-title":"J Gen Virol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.73.3.2115-2125.1999","article-title":"CD21-Dependent Infection of an Epithelial Cell Line, 293, by Epstein-Barr Virus","volume":"73","author":"Fingeroth","year":"1999","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1418974111","article-title":"Epstein-Barr Virus Replicating in Epithelial Cells","volume":"111","author":"Hutt-Fletcher","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2012.02.004","article-title":"The Biology of EBV Infection in Human Epithelial Cells","volume":"22","author":"Tsao","year":"2012","journal-title":"Semin Cancer Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/356347a0","article-title":"Epstein-Barr Virus Infection and Replication in a Human Epithelial Cell System","volume":"356","author":"Li","year":"1992","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810530106","article-title":"Structure of a Trimeric Variant of the Epstein-Barr Virus Glycoprotein B","volume":"106","author":"Backovic","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-22834-1_7","article-title":"Viral Entry","volume":"391","author":"Chesnokova","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular Responses to Viral Infection in Humans: Lessons From Epstein-Barr Virus","volume":"25","author":"Hislop","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2014.01.003","article-title":"Cellular Immune Controls Over Epstein-Barr Virus Infection: New Lessons From the Clinic and the Laboratory","volume":"35","author":"Rickinson","year":"2014","journal-title":"Trends Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","article-title":"The Immunology of Epstein-Barr Virus-Induced Disease","volume":"33","author":"Taylor","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00713","article-title":"The Global Landscape of EBV-Associated Tumors","volume":"9","author":"Shannon-Lowe","year":"2019","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.7150\/jca.37282","article-title":"Epstein Barr Virus Associated Lymphomas and Epithelia Cancers in Humans","volume":"11","author":"Ayee","year":"2020","journal-title":"J Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12875-019-0954-3","article-title":"Epstein-Barr Virus and Its Association With Disease - a Review of Relevance to General Practice","volume":"20","author":"Fugl","year":"2019","journal-title":"BMC Fam Pract"},{"key":"B44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","article-title":"Primary Epstein-Barr Virus Infection","volume":"102","author":"Dunmire","year":"2018","journal-title":"J Clin Virol"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511545313.024","article-title":"Gammaherpesviruses Entry and Early Events During Infection","volume-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","author":"Chandran","year":"2007"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.5.1873-1874.2006","article-title":"Increasing Incidence of Severe Epstein-Barr Virus-Related Infectious Mononucleosis: Surveillance Study","volume":"44","author":"Tattevin","year":"2006","journal-title":"J Clin Microbiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e0226436","DOI":"10.1371\/journal.pone.0226436","article-title":"Primary Epstein-Barr Virus Infection With and Without Infectious Mononucleosis","volume":"14","author":"Rostgaard","year":"2019","journal-title":"PloS One"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1004746","DOI":"10.1371\/journal.ppat.1004746","article-title":"Early Virological and Immunological Events in Asymptomatic Epstein-Barr Virus Infection in African Children","volume":"11","author":"Jayasooriya","year":"2015","journal-title":"PloS Pathog"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00382-17","article-title":"Asymptomatic Primary Infection With Epstein-Barr Virus: Observations on Young Adult Cases","volume":"91","author":"Abbott","year":"2017","journal-title":"J Virol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/514164","article-title":"Correlates of Illness Severity in Infectious Mononucleosis","volume":"25","author":"Odame","year":"2014","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1086\/421276","article-title":"Analysis of Immune Activation and Clinical Events in Acute Infectious Mononucleosis","volume":"190","author":"Williams","year":"2004","journal-title":"J Infect Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2014.04.009","article-title":"Animal Models of Epstein Barr Virus Infection","volume":"410","author":"Chatterjee","year":"2014","journal-title":"J Immunol Methods"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/01.mej.0000224431.36376.71","article-title":"Upper Airway Obstruction in Infectious Mononucleosis","volume":"14","author":"Glynn","year":"2007","journal-title":"Eur J Emerg Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2016.03.008","article-title":"Viral Carcinogenesis Beyond Malignant Transformation: EBV in the Progression of Human Cancers","volume":"24","author":"Elgui de Oliveira","year":"2016","journal-title":"Trends Microbiol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e792","DOI":"10.1097\/MD.0000000000000792","article-title":"Epstein-Barr Virus Infection and Gastric Cancer: A Systematic Review","volume":"94","author":"Chen","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05775.x","article-title":"Clinicopathological and Molecular Characteristics of Epstein-Barr Virus-Associated Gastric Carcinoma: A Meta-Analysis","volume":"24","author":"Lee","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30885","article-title":"Malaria, Epstein-Barr Virus Infection and the Pathogenesis of Burkitt\u2019s Lymphoma","volume":"141","author":"Mawson","year":"2017","journal-title":"Int J Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-22822-8_11","article-title":"Burkitt\u2019s Lymphoma","volume":"390","author":"Rochford","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24223","article-title":"Epstein-Barr Virus and the Pathogenesis of Burkitt\u2019s Lymphoma: More Questions Than Answers","volume":"124","author":"Bornkamm","year":"2009","journal-title":"Int J Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21438","article-title":"Hodgkin Lymphoma: A Review and Update on Recent Progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2007.1.204","article-title":"Epstein-Barr Virus and Hodgkin Lymphoma","author":"Ambinder","year":"2007","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198902233200806","article-title":"Detection of Epstein-Barr Viral Genomes in Reed-Sternberg Cells of Hodgkin\u2019s Disease","volume":"320","author":"Weiss","year":"1989","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.2.810.810","article-title":"Demonstration of Monoclonal EBV Genomes in Hodgkin\u2019s Disease and Ki-1-Positive Anaplastic Large Cell Lymphoma by Combined Southern Blot and in Situ Hybridization","volume":"74","author":"Anagnostopoulos","year":"1989","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of Gene-Modified Virus-Specific T Lymphocytes to Control Epstein-Barr-Virus-Related Lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus-Induced Lymphoma in Allogeneic Transplant Recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-551","article-title":"Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes","volume":"2","author":"Heslop","year":"1996","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-Term Outcome of EBV-Specific T-Cell Infusions to Prevent or Treat EBV-Related Lymphoproliferative Disease in Transplant Recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-22834-1_15","article-title":"Adoptive T-Cell Immunotherapy","volume":"391","author":"Gottschalk","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e1002308","DOI":"10.1371\/journal.ppat.1002308","article-title":"Soluble Rhesus Lymphocryptovirus Gp350 Protects Against Infection and Reduces Viral Loads in Animals That Become Infected With Virus After Challenge","volume":"7","author":"Sashihara","year":"2011","journal-title":"PloS Pathog"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890130310","article-title":"Comparative Immunogenicity Studies on Epstein-Barr Virus Membrane Antigen (MA) Gp340 With Novel Adjuvants in Mice, Rabbits, and Cotton-Top Tamarins","volume":"13","author":"Morgan","year":"1984","journal-title":"J Med Virol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890290114","article-title":"Validation of a First-Generation Epstein-Barr Virus Vaccine Preparation Suitable for Human Use","volume":"29","author":"Morgan","year":"1989","journal-title":"J Med Virol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-73-2-449","article-title":"Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope Glycoprotein Gp340 Produced From a Bovine Papillomavirus Expression Vector","volume":"73","author":"Finerty","year":"1992","journal-title":"J Gen Virol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199808)55:4<255::AID-JMV1>3.0.CO;2-#","article-title":"Immunization of Common Marmosets With Epstein-Barr Virus (EBV) Envelope Glycoprotein Gp340: Effect on Viral Shedding Following EBV Challenge","volume":"55","author":"Cox","year":"1998","journal-title":"J Med Virol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199611)50:3<263::AID-JMV9>3.0.CO;2-7","article-title":"Immunisation of Common Marmosets With Vaccinia Virus Expressing Epstein-Barr Virus (EBV) Gp340 and Challenge With EBV","volume":"50","author":"Mackett","year":"1996","journal-title":"J Med Virol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-74-3-501","article-title":"Replication-Defective Recombinant Adenovirus Expressing the Epstein-Barr Virus (EBV) Envelope Glycoprotein Gp340\/220 Induces Protective Immunity Against EBV-Induced Lymphomas in the Cottontop Tamarin","volume":"74","author":"Ragot","year":"1993","journal-title":"J Gen Virol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890250209","article-title":"Recombinant Vaccinia Virus Expressing Epstein-Barr Virus Glycoprotein Gp340 Protects Cottontop Tamarins Against EB Virus-Induced Malignant Lymphomas","volume":"25","author":"Morgan","year":"1988","journal-title":"J Med Virol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1086\/590502","article-title":"A New Humanized Mouse Model of Epstein-Barr Virus Infection That Reproduces Persistent Infection, Lymphoproliferative Disorder, and Cell-Mediated and Humoral Immune Responses","volume":"198","author":"Yajima","year":"2008","journal-title":"J Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-305979","article-title":"A Novel Animal Model of Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Humanized Mice","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.156","article-title":"The Different Epidemiologic Subtypes of Burkitt Lymphoma Share a Homogenous Micro RNA Profile Distinct From Diffuse Large B-Cell Lymphoma","volume":"25","author":"Lenze","year":"2011","journal-title":"Leukemia"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0271","article-title":"Epstein-Barr Virus-Associated Lymphomas","volume":"372","author":"Shannon-Lowe","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP64YOHAWLUMPK","article-title":"Burkitt Lymphoma in Brazil is Characterized by Geographically Distinct Clinicopathologic Features","volume":"130","author":"Queiroga","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2013.08.004","article-title":"Lymphomas Occurring Specifically in HIV-Infected Patients: From Pathogenesis to Pathology","volume":"23","author":"Gloghini","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.09013.x","article-title":"Epidemiology: Clues to the Pathogenesis of Burkitt Lymphoma","volume":"156","author":"Magrath","year":"2012","journal-title":"Br J Haematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2009.07.007","article-title":"How Does Epstein-Barr Virus (EBV) Complement the Activation of Myc in the Pathogenesis of Burkitt\u2019s Lymphoma","volume":"19","author":"Allday","year":"2009","journal-title":"Semin Cancer Biol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0270","article-title":"Epstein-Barr Virus Infection and Nasopharyngeal Carcinoma","volume":"372","author":"Tsao","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.3.1766-1775.1997","article-title":"Dominant-Negative Inhibitors of EBNA-1 of Epstein-Barr Virus","volume":"71","author":"Kirchmaier","year":"1997","journal-title":"J Virol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e1005331","DOI":"10.1371\/journal.ppat.1005331","article-title":"The Link Between Plasmodium Falciparum Malaria and Endemic Burkitt\u2019s Lymphoma-New Insight Into a 50-Year-Old Enigma","volume":"12","author":"Thorley-Lawson","year":"2016","journal-title":"PloS Pathog"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-180315","article-title":"HIV-Associated Lymphomas and Gamma-Herpesviruses","volume":"113","author":"Carbone","year":"2009","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90943-J","article-title":"Expression of Epstein-Barr Virus Latent Gene Products in Tumour Cells of Hodgkin\u2019s Disease","volume":"337","author":"Pallesen","year":"1991","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T","article-title":"Epstein-Barr Virus-Associated Hodgkin\u2019s Disease: Epidemiologic Characteristics in International Data","volume":"70","author":"Glaser","year":"1997","journal-title":"Int J Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10090285","article-title":"Co-Expression of the Epstein-Barr Virus-Encoded Latent Membrane Proteins and the Pathogenesis of Classic Hodgkin Lymphoma","volume":"10","author":"Vrzalikova","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B93","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/annonc\/7.suppl_4.S27","article-title":"Single Cell Analysis of Hodgkin\/Reed-Sternberg Cells","author":"Kuppers","year":"1996","journal-title":"Ann Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.4.1495","article-title":"Hodgkin and Reed-Sternberg Cells in Hodgkin\u2019s Disease Represent the Outgrowth of a Dominant Tumor Clone Derived From (Crippled) Germinal Center B Cells","volume":"184","author":"Kanzler","year":"1996","journal-title":"J Exp Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1995.tb55877.x","article-title":"Hodgkin\u2019s Disease: Clonal Ig Gene Rearrangements in Hodgkin and Reed-Sternberg Cells Picked From Histological Sections","volume":"764","author":"Kuppers","year":"1995","journal-title":"Ann N Y Acad Sci"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119849","article-title":"Constitutive Nuclear factor-kappaB-RelA Activation is Required for Proliferation and Survival of Hodgkin\u2019s Disease Tumor Cells","volume":"100","author":"Bargou","year":"1997","journal-title":"J Clin Invest"},{"key":"B97","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/path.1725","article-title":"Constitutive Activation of Phosphatidyl-Inositide 3 Kinase Contributes to the Survival of Hodgkin\u2019s Lymphoma Cells Through a Mechanism Involving Akt Kinase and mTOR","volume":"205","author":"Dutton","year":"2005","journal-title":"J Pathol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.11.3064","article-title":"Latent Membrane Protein 1 of Epstein-Barr Virus Interacts With JAK3 and Activates STAT Proteins","volume":"18","author":"Gires","year":"1999","journal-title":"EMBO J"},{"key":"B99","article-title":"The Epstein-Barr Virus Latent Membrane Protein-1 (LMP1) Mediates Activation of NF-Kappa B and Cell Surface Phenotype via Two Effector Regions in Its Carboxy-Terminal Cytoplasmic Domain","volume":"10","author":"Huen","year":"1995","journal-title":"Oncogene"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403750","article-title":"STAT3 is Essential for Hodgkin Lymphoma Cell Proliferation and is a Target of Tyrphostin AG17 Which Confers Sensitization for Apoptosis","volume":"19","author":"Holtick","year":"2005","journal-title":"Leukemia"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201694","article-title":"Activation of the Cjun N-Terminal Kinase (JNK) Pathway by the Epstein-Barr Virus-Encoded Latent Membrane Protein 1 (LMP1)","volume":"16","author":"Eliopoulos","year":"1998","journal-title":"Oncogene"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)35741-7","article-title":"The Epstein-Barr Virus LMP1 Gene Product Induces A20 Zinc Finger Protein Expression by Activating Nuclear Factor Kappa B","volume":"267","author":"Laherty","year":"1992","journal-title":"J Biol Chem"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.21.6478","article-title":"Epstein-Barr Virus Latent Membrane Protein-1 Triggers AP-1 Activity via the C-Jun N-Terminal Kinase Cascade","volume":"16","author":"Kieser","year":"1997","journal-title":"EMBO J"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.2.459.459","article-title":"Expression of Bcl-2 in Burkitt\u2019s Lymphoma Cell Lines: Induction by Latent Epstein-Barr Virus Genes","volume":"80","author":"Finke","year":"1992","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90007-L","article-title":"Induction of Bcl-2 Expression by Epstein-Barr Virus Latent Membrane Protein 1 Protects Infected B Cells From Programmed Cell Death","volume":"65","author":"Henderson","year":"1991","journal-title":"Cell"},{"key":"B106","article-title":"Expression of the Epstein Barr Virus Transforming Protein LMP1 Causes a Rapid and Transient Stimulation of the Bcl-2 Homologue Mcl-1 Levels in B-Cell Lines","volume":"56","author":"Wang","year":"1996","journal-title":"Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.3.1101-1113.2000","article-title":"Epstein-Barr Virus LMP2A-Induced B-Cell Survival in Two Unique Classes of EmuLMP2A Transgenic Mice","volume":"74","author":"Caldwell","year":"2000","journal-title":"J Virol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00537-07","article-title":"Epstein-Barr Virus Latent Membrane Protein 2A Mediates Transformation Through Constitutive Activation of the Ras\/PI3-K\/Akt Pathway","volume":"81","author":"Fukuda","year":"2007","journal-title":"J Virol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.9.5499-5506.2005","article-title":"Modulation of the Cell Growth Regulator mTOR by Epstein-Barr Virus-Encoded LMP2A","volume":"79","author":"Moody","year":"2005","journal-title":"J Virol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80623-8","article-title":"Epstein-Barr Virus LMP2A Drives B Cell Development and Survival in the Absence of Normal B Cell Receptor Signals","volume":"9","author":"Caldwell","year":"1998","journal-title":"Immunity"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3109\/08830180109045591","article-title":"The Effects of the Epstein-Barr Virus Latent Membrane Protein 2A on B Cell Function","volume":"20","author":"Merchant","year":"2001","journal-title":"Int Rev Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2327","article-title":"Epstein-Barr Virus Infection In Vitro can Rescue Germinal Center B Cells With Inactivated Immunoglobulin Genes","volume":"106","author":"Chaganti","year":"2005","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2342","article-title":"Transformation of BCR-Deficient Germinal-Center B Cells by EBV Supports a Major Role of the Virus in the Pathogenesis of Hodgkin and Posttransplantation Lymphomas","volume":"106","author":"Bechtel","year":"2005","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2341","article-title":"Rescue of \"Crippled\" Germinal Center B Cells From Apoptosis by Epstein-Barr Virus","volume":"106","author":"Mancao","year":"2005","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-090142","article-title":"Epstein-Barr Virus Latent Membrane Protein 2A is a B-Cell Receptor Mimic and Essential for B-Cell Survival","volume":"110","author":"Mancao","year":"2007","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1018","article-title":"Epstein-Barr Virus (EBV) LMP2A Induces Alterations in Gene Transcription Similar to Those Observed in Reed-Sternberg Cells of Hodgkin Lymphoma","volume":"102","author":"Portis","year":"2003","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/path.4198","article-title":"Suppression of the LMP2A Target Gene, EGR-1, Protects Hodgkin\u2019s Lymphoma Cells From Entry to the EBV Lytic Cycle","volume":"230","author":"Vockerodt","year":"2013","journal-title":"J Pathol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2017.03.15","article-title":"Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification","volume":"51","author":"Kim","year":"2017","journal-title":"J Pathol Transl Med"},{"key":"B119","doi-asserted-by":"crossref","DOI":"10.1034\/j.1600-6143.2001.10202.x","article-title":"Management of Epstein-Barr Virus-Induced Post-Transplant Lymphoproliferative Disease in Recipients of Solid Organ Transplantation","volume":"1","author":"Green","year":"2001","journal-title":"Am J Transplant"},{"key":"B120","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1097\/TXD.0000000000000557","article-title":"Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management","volume":"2","author":"Nijland","year":"2016","journal-title":"Transplant Direct"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2010.10.016","article-title":"Post-Transplant Lymphoproliferative Disease (PTLD): Pharmacological, Virological and Other Determinants","volume":"63","author":"Stojanova","year":"2011","journal-title":"Pharmacol Res"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01650.x","article-title":"Epstein-Barr Virus: Evasive Maneuvers in the Development of PTLD","volume":"7","author":"Snow","year":"2007","journal-title":"Am J Transplant"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041407","article-title":"Emerging Cellular Therapies for Cancer","volume":"37","author":"Guedan","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-012-0333-z","article-title":"Nasopharyngeal Carcinoma","volume":"6","author":"Carle","year":"2012","journal-title":"Head Neck Pathol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/S1044579X02000858","article-title":"Epidemiology of Nasopharyngeal Carcinoma","volume":"12","author":"Yu","year":"2002","journal-title":"Semin Cancer Biol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-06-0353","article-title":"The Enigmatic Epidemiology of Nasopharyngeal Carcinoma","volume":"15","author":"Chang","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1177\/030089167806400509","article-title":"Proposal for a New Histopathological Classification of the Carcinomas of the Nasopharynx","volume":"64","author":"Micheau","year":"1978","journal-title":"Tumori"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2013.05.018","article-title":"Pathogenic Role of Epstein-Barr Virus Latent Membrane Protein-1 in the Development of Nasopharyngeal Carcinoma","volume":"337","author":"Yoshizaki","year":"2013","journal-title":"Cancer Lett"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e0153498","DOI":"10.1371\/journal.pone.0153498","article-title":"Characterization of the Variability of Epstein-Barr Virus Genes in Nasopharyngeal Biopsies: Potential Predictors for Carcinoma Progression","volume":"11","author":"Banko","year":"2016","journal-title":"PloS One"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-22822-8_14","article-title":"Nasopharyngeal Carcinoma: An Evolving Role for the Epstein-Barr Virus","volume":"390","author":"Raab-Traub","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e1004561","DOI":"10.1371\/journal.ppat.1004561","article-title":"The Epstein-Barr Virus Encoded BART miRNAs Potentiate Tumor Growth In Vivo","volume":"11","author":"Qiu","year":"2015","journal-title":"PloS Pathog"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02104-08","article-title":"Comprehensive Profiling of Epstein-Barr Virus microRNAs in Nasopharyngeal Carcinoma","volume":"83","author":"Cosmopoulos","year":"2009","journal-title":"J Virol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00853-12","article-title":"Epstein-Barr Virus Latent Membrane Protein-2A Induces ITAM\/Syk- and Akt-Dependent Epithelial Migration Through Alphav-Integrin Membrane Translocation","volume":"86","author":"Fotheringham","year":"2012","journal-title":"J Virol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.24.15430-15442.2005","article-title":"Epstein-Barr-Virus-Encoded LMP2A Induces Primary Epithelial Cell Migration and Invasion: Possible Role in Nasopharyngeal Carcinoma Metastasis","volume":"79","author":"Pegtel","year":"2005","journal-title":"J Virol"},{"key":"B135","article-title":"Activation of Nuclear factor-kappaB P50 Homodimer\/Bcl-3 Complexes in Nasopharyngeal Carcinoma","volume":"63","author":"Thornburg","year":"2003","journal-title":"Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2011.07.004","article-title":"Epstein-Barr Virus-Associated Gastric Carcinoma","volume":"207","author":"Fukayama","year":"2011","journal-title":"Pathol Res Pract"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.5009\/gnl.2011.5.2.143","article-title":"Pathology of Epstein-Barr Virus-Associated Gastric Carcinoma and Its Relationship to Prognosis","volume":"5","author":"Song","year":"2011","journal-title":"Gut Liver"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.061","article-title":"EBV-Positive Gastric Adenocarcinomas: A Distinct Clinicopathologic Entity With a Low Frequency of Lymph Node Involvement","volume":"22","author":"van Beek","year":"2004","journal-title":"J Clin Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0475","article-title":"Epstein-Barr Virus Gene Expression and Latency Pattern in Gastric Carcinomas: A Systematic Review","volume":"13","author":"Ribeiro","year":"2017","journal-title":"Future Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480","article-title":"Comprehensive Molecular Characterization of Gastric Adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1159\/000434683","article-title":"Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations","volume":"82","author":"Abe","year":"2015","journal-title":"Pathobiology"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3919","article-title":"Epstein-Barr Virus Infection as an Epigenetic Driver of Tumorigenesis","volume":"72","author":"Kaneda","year":"2012","journal-title":"Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","first-page":"817238","DOI":"10.1155\/2015\/817238","article-title":"Risk Factors Associated With the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review","volume":"2015","author":"McKay","year":"2015","journal-title":"BioMed Res Int"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-010-9201-3","article-title":"Epstein-Barr Virus Infection and Multiple Sclerosis: A Review","volume":"5","author":"Ascherio","year":"2010","journal-title":"J Neuroimmune Pharmacol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/ane.12294","article-title":"Targeting Epstein-Barr Virus Infection as an Intervention Against Multiple Sclerosis","volume":"131","author":"Jons","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124714","article-title":"Epstein-Barr Virus-Specific T Cell Therapy for Progressive Multiple Sclerosis","volume":"3","author":"Pender","year":"2018","journal-title":"JCI Insight"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26188","article-title":"Epstein-Barr Virus-Immortalized B Lymphocytes Exacerbate Experimental Autoimmune Encephalomyelitis in Xenograft Mice","volume":"93","author":"Polepole","year":"2021","journal-title":"J Med Virol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/eji.202048655","article-title":"Attenuated Immune Control of Epstein-Barr Virus in Humanized Mice is Associated With the Multiple Sclerosis Risk Factor HLA-Dr15","volume":"51","author":"Zdimerova","year":"2021","journal-title":"Eur J Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1177\/1352458508100037","article-title":"Effects of Infectious Mononucleosis and HLA-DRB1*15 in Multiple Sclerosis","volume":"15","author":"Nielsen","year":"2009","journal-title":"Mult Scler"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global Burden of Cancers Attributable to Infections in 2008: A Review and Synthetic Analysis","volume":"13","author":"de Martel","year":"2012","journal-title":"Lancet Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/318287a0","article-title":"Protection of Cottontop Tamarins Against Epstein-Barr Virus-Induced Malignant Lymphoma by a Prototype Subunit Vaccine","volume":"318","author":"Epstein","year":"1985","journal-title":"Nature"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(88)90509-0","article-title":"Antigenic Analysis of the Epstein-Barr Virus Major Membrane Antigen (Gp350\/220) Expressed in Yeast and Mammalian Cells: Implications for the Development of a Subunit Vaccine","volume":"166","author":"Emini","year":"1988","journal-title":"Virology"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-69-8-2093","article-title":"Prevention of Epstein-Barr (EB) Virus-Induced Lymphoma in Cottontop Tamarins by Vaccination With the EB Virus Envelope Glycoprotein Gp340 Incorporated Into Immune-Stimulating Complexes","volume":"69","author":"Morgan","year":"1988","journal-title":"J Gen Virol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(94)90240-2","article-title":"Immunization of Cottontop Tamarins and Rabbits With a Candidate Vaccine Against the Epstein-Barr Virus Based on the Major Viral Envelope Glycoprotein Gp340 and Alum","volume":"12","author":"Finerty","year":"1994","journal-title":"Vaccine"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00248-5","article-title":"Expression of Epstein-Barr Virus Gp350 as a Single Chain Glycoprotein for an EBV Subunit Vaccine","volume":"17","author":"Jackman","year":"1999","journal-title":"Vaccine"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1086\/523813","article-title":"Recombinant Gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein-Barr Virus Vaccine in Healthy Young Adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.04.071","article-title":"A Novel Tetrameric Gp350 1-470 as a Potential Epstein-Barr Virus Vaccine","volume":"31","author":"Cui","year":"2013","journal-title":"Vaccine"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.043","article-title":"Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site","volume":"162","author":"Kanekiyo","year":"2015","journal-title":"Cell"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.06.021","article-title":"Rabbits Immunized With Epstein-Barr Virus Gh\/gL or gB Recombinant Proteins Elicit Higher Serum Virus Neutralizing Activity Than Gp350","volume":"34","author":"Cui","year":"2016","journal-title":"Vaccine"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00932","article-title":"Immunization With Fc-Based Recombinant Epstein-Barr Virus Gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB\/c Mice Model","volume":"9","author":"Zhao","year":"2018","journal-title":"Front Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization With Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030285","article-title":"Immunization With Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice From Lethal Dose EBV Challenge","volume":"9","author":"Cui","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05598-11","article-title":"A Virus-Like Particle-Based Epstein-Barr Virus Vaccine","volume":"85","author":"Ruiss","year":"2011","journal-title":"J Virol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"e1007464","DOI":"10.1371\/journal.ppat.1007464","article-title":"Immunogenic Particles With a Broad Antigenic Spectrum Stimulate Cytolytic T Cells and Offer Increased Protection Against EBV Infection Ex Vivo and in Mice","volume":"14","author":"van Zyl","year":"2018","journal-title":"PloS Pathog"},{"key":"B165","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12967-015-0415-2","article-title":"A Chimeric EBV Gp350\/220-Based VLP Replicates the Virion B-Cell Attachment Mechanism and Elicits Long-Lasting Neutralizing Antibodies in Mice","volume":"13","author":"Ogembo","year":"2015","journal-title":"J Transl Med"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13770","article-title":"Novel Epstein-Barr Virus-Like Particles Incorporating Gh\/gL-EBNA1 or gB-LMP2 Induce High Neutralizing Antibody Titers and EBV-Specific T-Cell Responses in Immunized Mice","volume":"8","author":"Perez","year":"2017","journal-title":"Oncotarget"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II Studies to Evaluate Safety and Immunogenicity of a Recombinant Gp350 Epstein-Barr Virus Vaccine in Healthy Adults","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.21.10142-10152.2000","article-title":"Infectious Epstein-Barr Virus Lacking Major Glycoprotein BLLF1 (Gp350\/220) Demonstrates the Existence of Additional Viral Ligands","volume":"74","author":"Janz","year":"2000","journal-title":"J Virol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.09.093","article-title":"Recent Advances in Recombinant Protein-Based Malaria Vaccines","volume":"33","author":"Draper","year":"2015","journal-title":"Vaccine"},{"key":"B170","doi-asserted-by":"publisher","first-page":"30357","DOI":"10.1038\/srep30357","article-title":"Production of Full-Length Soluble Plasmodium Falciparum RH5 Protein Vaccine Using a Drosophila Melanogaster Schneider 2 Stable Cell Line System","volume":"6","author":"Hjerrild","year":"2016","journal-title":"Sci Rep"},{"key":"B171","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/14760584.2018.1526085","article-title":"A Fifty-Year Odyssey: Prospects for a Cytomegalovirus Vaccine in Transplant and Congenital Infection","volume":"17","author":"Diamond","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1593729","article-title":"Development of Novel Vaccines Against Human Cytomegalovirus","volume":"15","author":"Cui","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.07.056","article-title":"Novel Trimeric Human Cytomegalovirus Glycoprotein B Elicits a High-Titer Neutralizing Antibody Response","volume":"36","author":"Cui","year":"2018","journal-title":"Vaccine"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020179","article-title":"Immunization With Human Cytomegalovirus Core Fusion Machinery and Accessory Envelope Proteins Elicit Strong Synergistic Neutralizing Activities","volume":"8","author":"Cui","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B175","article-title":"Vaccine Compositions of Herpesvirus Envelope Protein Combinations to Induce Immune Response","author":"Cui","year":"2021","journal-title":"USPTO"},{"key":"B176","doi-asserted-by":"publisher","first-page":"e1005549","DOI":"10.1371\/journal.ppat.1005549","article-title":"Early T Cell Recognition of B Cells Following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination","volume":"12","author":"Brooks","year":"2016","journal-title":"PloS Pathog"},{"key":"B177","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1084\/jem.20051287","article-title":"Control of Epstein-Barr Virus Infection In Vitro by T Helper Cells Specific for Virion Glycoproteins","volume":"203","author":"Adhikary","year":"2006","journal-title":"J Exp Med"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-00720-9","article-title":"Covid-19 Commission of Accademia Nazionale Dei Lincei R. COVID-19 Vaccines: Where We Stand and Challenges Ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell Death Differ"},{"key":"B179","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 Vaccines Strategies: A Comprehensive Review of Phase 3 Candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.10.1649","article-title":"Human CD4(+) T Lymphocytes Consistently Respond to the Latent Epstein-Barr Virus Nuclear Antigen EBNA1","volume":"191","author":"Munz","year":"2000","journal-title":"J Exp Med"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1172\/JCI22053","article-title":"Critical Role of EBNA1-Specific CD4+ T Cells in the Control of Mouse Burkitt Lymphoma In Vivo","volume":"114","author":"Fu","year":"2004","journal-title":"J Clin Invest"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040191","article-title":"Endogenous Presentation of CD8+ T Cell Epitopes From Epstein-Barr Virus-Encoded Nuclear Antigen 1","volume":"199","author":"Tellam","year":"2004","journal-title":"J Exp Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.66.5.2689-2697.1992","article-title":"Epstein-Barr Virus Latent Gene Transcription in Nasopharyngeal Carcinoma Cells: Coexpression of EBNA1, LMP1, and LMP2 Transcripts","volume":"66","author":"Brooks","year":"1992","journal-title":"J Virol"},{"key":"B184","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.158.7.3325","article-title":"Conserved CTL Epitopes Within EBV Latent Membrane Protein 2: A Potential Target for CTL-Based Tumor Therapy","volume":"158","author":"Lee","year":"1997","journal-title":"J Immunol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.6.4137","article-title":"Characterization of Latent Membrane Protein 2 Specificity in CTL Lines From Patients With EBV-Positive Nasopharyngeal Carcinoma and Lymphoma","volume":"175","author":"Straathof","year":"2005","journal-title":"J Immunol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30541","article-title":"Epstein-Barr Virus-Specific Adoptive Immunotherapy for Recurrent, Metastatic Nasopharyngeal Carcinoma","volume":"123","author":"Huang","year":"2017","journal-title":"Cancer"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31828bd87b","article-title":"Delayed-Type Hypersensitivity (DTH) Immune Response Related With EBV-DNA in Nasopharyngeal Carcinoma Treated With Autologous Dendritic Cell Vaccination After Radiotherapy","volume":"36","author":"Li","year":"2013","journal-title":"J Immunother"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c16-00114","article-title":"The Safety and Immunological Effects of Rad5-EBV-LMP2 Vaccine in Nasopharyngeal Carcinoma Patients: A Phase I Clinical Trial and Two-Year Follow-Up","volume":"64","author":"Si","year":"2016","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein-Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients With EBV-Positive Cancer","volume":"20","author":"Taylor","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B191","article-title":"Immunization With Epstein-Barr Virus (EBV) Peptide-Pulsed Dendritic Cells Induces Functional CD8+ T-Cell Immunity and may Lead to Tumor Regression in Patients With EBV-Positive Nasopharyngeal Carcinoma","volume":"62","author":"Lin","year":"2002","journal-title":"Cancer Res"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.2.768-778.2004","article-title":"Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4+- and CD8+-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma","volume":"78","author":"Taylor","year":"2004","journal-title":"J Virol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2299","article-title":"High Levels of Antibody That Neutralize B-Cell Infection of Epstein-Barr Virus and That Bind EBV Gp350 Are Associated With a Lower Risk of Nasopharyngeal Carcinoma","volume":"22","author":"Coghill","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders After Allogeneic Bone Marrow Transplantation","volume":"330","author":"Papadopoulos","year":"1994","journal-title":"N Engl J Med"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.18.10391","article-title":"Activation and Adoptive Transfer of Epstein-Barr Virus-Specific Cytotoxic T Cells in Solid Organ Transplant Patients With Posttransplant Lymphoproliferative Disease","volume":"96","author":"Khanna","year":"1999","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021782","article-title":"Treatment of Solid Organ Transplant Recipients With Autologous Epstein Barr Virus-Specific Cytotoxic T Lymphocytes (CTLs)","volume":"108","author":"Savoldo","year":"2006","journal-title":"Blood"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2592","article-title":"Infusion of Autologous Epstein-Barr Virus (EBV)-Specific Cytotoxic T Cells for Prevention of EBV-Related Lymphoproliferative Disorder in Solid Organ Transplant Recipients With Evidence of Active Virus Replication","volume":"99","author":"Comoli","year":"2002","journal-title":"Blood"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.6195","article-title":"Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes","volume":"23","author":"Comoli","year":"2005","journal-title":"J Clin Oncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181f3cbf4","article-title":"Adoptive Transfer of EBV-Specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma","volume":"33","author":"Louis","year":"2010","journal-title":"J\u00a0Immunother"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.242","article-title":"Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatment of Metastatic and\/or Locally Recurrent Nasopharyngeal Carcinoma","volume":"22","author":"Chia","year":"2014","journal-title":"Mol Ther"},{"key":"B201","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0203-T","article-title":"Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-Cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma","volume":"3","author":"Zheng","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.475","article-title":"A Novel Epstein-Barr Virus-Latent Membrane Protein-1-Specific T-Cell Receptor for TCR Gene Therapy","volume":"118","author":"Cho","year":"2018","journal-title":"Br J Cancer"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S221040","article-title":"CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo","volume":"12","author":"Tang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.7555\/JBR.28.20140066","article-title":"T Cells Expressing a LMP1-Specific Chimeric Antigen Receptor Mediate Antitumor Effects Against LMP1-Positive Nasopharyngeal Carcinoma Cells In Vitro and In Vivo","volume":"28","author":"Tang","year":"2014","journal-title":"J BioMed Res"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","article-title":"Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Treatment of Patients With EBV-Positive Relapsed Hodgkin\u2019s Disease","volume":"91","author":"Roskrow","year":"1998","journal-title":"Blood"},{"key":"B207","doi-asserted-by":"publisher","first-page":"e1273311","DOI":"10.1080\/2162402X.2016.1273311","article-title":"Pre-Emptive and Therapeutic Adoptive Immunotherapy for Nasopharyngeal Carcinoma: Phenotype and Effector Function of T Cells Impact on Clinical Response","volume":"6","author":"Smith","year":"2017","journal-title":"Oncoimmunology"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1514","article-title":"Generating CTLs Against the Subdominant Epstein-Barr Virus LMP1 Antigen for the Adoptive Immunotherapy of EBV-Associated Malignancies","volume":"101","author":"Gottschalk","year":"2003","journal-title":"Blood"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-Engineered T Cells Targeting E7 for Patients With Metastatic HPV-Associated Epithelial Cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01689","article-title":"TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals","volume":"11","author":"Manfredi","year":"2020","journal-title":"Front Immunol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T Cell Therapy for Cancer in the Clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Immunol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1006\/clim.2000.4977","article-title":"Retroviral Transduction of a T Cell Receptor Specific for an Epstein-Barr Virus-Encoded Peptide","volume":"98","author":"Orentas","year":"2001","journal-title":"Clin Immunol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/intimm\/dxh401","article-title":"T Cell Re-Targeting to EBV Antigens Following TCR Gene Transfer: CD28-Containing Receptors Mediate Enhanced Antigen-Specific IFNgamma Production","volume":"18","author":"Schaft","year":"2006","journal-title":"Int Immunol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3358","article-title":"A New Cloning and Expression System Yields and Validates TCRs From Blood Lymphocytes of Patients With Cancer Within 10 Days","volume":"19","author":"Kobayashi","year":"2013","journal-title":"Nat Med"},{"key":"B215","doi-asserted-by":"publisher","first-page":"716926","DOI":"10.1155\/2011\/716926","article-title":"Evaluation of Epstein-Barr Virus Latent Membrane Protein 2 Specific T-Cell Receptors Driven by T-Cell Specific Promoters Using Lentiviral Vector","volume":"2011","author":"Yang","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061400","article-title":"Redirecting T Cells Against Epstein-Barr Virus Infection and Associated Oncogenesis","volume":"9","author":"Munz","year":"2020","journal-title":"Cells"},{"key":"B217","doi-asserted-by":"publisher","first-page":"e22590","DOI":"10.4161\/onci.22590","article-title":"Human MHC Class I-Restricted High Avidity CD4(+) T Cells Generated by Co-Transfer of TCR and CD8 Mediate Efficient Tumor Rejection In Vivo","volume":"2","author":"Xue","year":"2013","journal-title":"Oncoimmunology"},{"key":"B218","doi-asserted-by":"publisher","first-page":"e1007748","DOI":"10.1371\/journal.ppat.1007748","article-title":"CD8+ T Cells Retain Protective Functions Despite Sustained Inhibitory Receptor Expression During Epstein-Barr Virus Infection In Vivo","volume":"15","author":"Chatterjee","year":"2019","journal-title":"PloS Pathog"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein Barr Virus Specific Cytotoxic T Lymphocytes Expressing the Anti-CD30zeta Artificial Chimeric T-Cell Receptor for Immunotherapy of Hodgkin Disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of Donor-Derived CD19-Redirected Virus-Specific T Cells for B-Cell Malignancies Relapsed After Allogeneic Stem Cell Transplant: A Phase 1 Study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"B221","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41375-020-0792-2","article-title":"CAR T-Cells That Target Acute B-Lineage Leukemia Irrespective of CD19 Expression","volume":"35","author":"Fousek","year":"2021","journal-title":"Leukemia"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002062","article-title":"Common Variable Immune Deficiency: Case Studies","volume":"134","author":"Cunningham-Rundles","year":"2019","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.734471\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T11:47:58Z","timestamp":1673437678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.734471\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":224,"alternative-id":["10.3389\/fimmu.2021.734471"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.734471","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"article-number":"734471"}}